Some may be tempted to declare "capitulation!" in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as one notorious and maligned bull bids farewell.
The fact of the matter is Pershing Square decision only came after a substantial year-long commitment to help Valeant sell key assets, establish a new management team and overhaul of the company's board. (NYSE:VRX) where 3 analyst have rated the stock as Strong Buy, 0 analysts said it's a Buy, 13 rated the stock as Hold, 4 analysts reported Underperform and 1 analysts gave their recommendations as Sell.
Valeant Pharmaceuticals Inc's stock price fell to its lowest level in eight years yesterday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company's most pressing problem: raising capital to cut its roughly $30 billion debt pile.
The Company got Downgrade by Morgan Stanley on 15-Dec-16 from Overweight to Equal-Weight. (NYSE:VRX) reported its Actual EPS of $1.26/share. For the Current Quarter, 15 analysts are projecting the mean EPS to be $0.95/share.
In the past 6 months, 6 Insider purchases and 3 Insider Sales were made in which 30775 shares were traded as Insider purchases and 4328940 shares were exchanged as Insider Sales. The company's market cap is $3.83 billion.
The company has a 50-day moving average price of $14.14 and a 200 day moving average price of $18.57. Deutsche Bank Initiates Coverage on Valeant Pharmaceuticals International, Inc. Tightening the gaze, stock performance for the last 5 trading days is -7.32%. The firm earned $2.40 billion during the quarter, compared to analysts' expectations of $2.34 billion.
Several investment firms issued their expert ratings on Valeant Pharmaceuticals International, Inc. The current consensus recommendation provided by covering analysts is 3.00.
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its earnings results on Tuesday, February 28th.
Institutional investors have recently added to or reduced their stakes in the company. Kistler Tiffany Companies LLC boosted its position in Valeant Pharmaceuticals Intl by 95.5% in the third quarter. The Insider Ownership of the company now is 2.3 percent, and Institutional Ownership is 66.8 percent.
Hedge funds have recently bought and sold shares of the company. For the quarter, shares have been noted at -25.00%. Finally, Hexavest Inc. raised its position in Valeant Pharmaceuticals Intl by 110.1% in the third quarter. LeJeune Puetz Investment Counsel LLC purchased a new stake in Valeant Pharmaceuticals Intl during the fourth quarter valued at about $123,000. Analysts giving shares a rating of 1 or 2 would be indicating a Buy. And Ackman hasn't been the only loser from Valeant's plunge, which has also dinged hedge-fund manager John Paulson, and cost Bob Goldfarb, the CEO of Sequoia-fund manager Ruane, Cunniff & Goldfarb, his job.
The analysts offering Earnings Estimates for the company were believing that Valeant Pharmaceuticals International, Inc. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).